Based on the Trevi Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Trevi Therapeutics Inc is USD 7.38 over the next 12 months. Trevi Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Trevi Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Trevi Therapeutics Inc’s stock price was USD 2.91. Trevi Therapeutics Inc’s stock price has changed by +5.82% over the past week, -9.35% over the past month and +155.26% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for TRVI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
